Key Highlights

  • J&J shares are trading down 1.31% at $269.62, against a previous close of $273.20.
  • Three Impella analyses covering 1,379 patients showed lower mortality than CHIP-BCIS3.
  • PROTECT IV randomized trial results are anticipated in 2027.

Johnson & Johnson (NYSE:JNJ) shares are trading down 1.31% at $269.62, against a previous close of $273.20, as defensive healthcare names lag a risk-on, oil-driven rotation into cyclicals. The company is presenting fresh MedTech data at the Transcatheter Cardiovascular Therapeutics meeting, where analyses show lower mortality with Impella heart pumps than the recently reported CHIP-BCIS3 trial.

Johnson & Johnson is a New Brunswick, New Jersey-based healthcare company founded in 1886. Following the 2023 separation of its consumer business, it operates two segments. Innovative Medicine, about 64% of 2025 revenue, focuses on oncology, immunology, neuroscience, cardiovascular and metabolism, and pulmonary hypertension. MedTech, about 36% of revenue, offers cardiovascular, orthopaedics, surgery and vision solutions. The company employs roughly 141,000 people and competes with large pharmaceutical and medical device peers.

Three Analyses Presented at TCT

The data come from real-world and observational registry analyses covering 1,379 patients who received Impella-supported high-risk percutaneous coronary intervention, known as HRPCI, at hospitals in the United States and Europe. They show lower in-hospital cardiovascular mortality and lower 30-day and 90-day mortality than reported in CHIP-BCIS3.

The TRI-GUARD-PCI registry analysis covered 279 patients undergoing elective protected PCI in Germany, Switzerland and Austria. All-cause mortality was 6.1% at 30 days and 7.9% at 180 days, lower than in the CHIP-BCIS3 trial curve. A U.S. registry analysis of 522 patients showed cardiovascular mortality of 3.4% at discharge, compared with about 8% in CHIP-BCIS3, and Kaplan-Meier estimates of 4.7% at 30 days and 6.5% at 90 days.

A PROTECT III analysis identified 578 Impella-supported patients who would have met the CHIP-BCIS3 entry criteria. In-hospital all-cause mortality for that group was 4.7%, against an estimated 8% in CHIP-BCIS3.

Differences in Support and Patient Selection

The company's chief medical and scientific officer for Heart Recovery said outcomes depend not only on the device but on how and when it is used, from patient selection and procedural approach to post-procedural management and critical care. The lead author of the U.S. registry analysis noted that in the CHIP-BCIS3 treatment arm the device was removed before patients left the catheterization lab, whereas in the registry one in six patients were supported for more than three hours, which suggests a possible link between duration of support and outcomes.

These are observational comparisons across different study designs, so they provide context rather than a head-to-head result. The press release notes that the two physicians quoted are paid consultants for J&J MedTech and were not compensated for their quotes.

Why the Shares Are Lower and What to Watch

The news is seen as modest. Abiomed, the maker of Impella, is about 1.6% of sales, and results from the randomized PROTECT IV trial are not due until 2027. Impella has been used to treat more than 450,000 patients globally, and the company continues to study it across a range of coronary conditions.

Investors are also weighing a premium valuation near 52-week highs, with the stock up roughly 34% this year, along with softness in MedTech. J&J's Shockwave Javelin catheter also met both primary goals in a pivotal study, according to market commentary. The shares trade within a 52-week range of $185.12 to $282.02, offer a Dividend Yield of 1.96% and have trailing Earnings Per Share of $10.73. The consensus price target sits near $276.

PROTECT IV will be the key test of the registry findings in a randomized setting, and it should show whether the lower mortality seen in real-world data holds up against a control arm.